| Literature DB >> 23775892 |
Richard J Q McNally1, Charles Stiller, Tim J Vincent, Michael F G Murphy.
Abstract
Previously, we identified space-time clustering in certain childhood cancers. This study aimed to determine whether there was cross-space-time clustering between different diagnostic groups. A total of 32,295 cases were diagnosed during 1969-1993. Cross-space-time clustering was analyzed by a second-order procedure based on Diggle's method. Locations were birth and diagnosis addresses. The following space-time combinations were examined: address and date of birth; address at birth and date of diagnosis; address and date of diagnosis. Cross-space-time clustering analyses considered clustering pairs of cases from two different diagnostic groups. Formal statistical significance was taken as p < 0.00067 and marginal significance 0.01 > p ≥ 0.00067. Based on address at birth and date of diagnosis, there was statistically significant cross-clustering between cases of HL and intracranial and intraspinal embryonal tumors (IIET), both aged 0-14 years (p < 0.0001). Based on address and date of birth, there was marginally significant cross-clustering between cases of lymphoid leukemia (LL) aged 5-14 years and Hodgkin lymphoma (HL) aged 0-14 years (p = 0.0019). Based on address and date of diagnosis there was marginally significant cross-clustering between cases of LL aged 1-4 years and soft tissue sarcoma (STS) aged 0-14 years (p = 0.0041). Findings from this study are consistent with possible common aetiological factors between different diagnostic groups. They suggest a common aetiology for the following pairs of diagnostic groups: HL and IIET; older cases of LL and HL; younger cases of LL and STS. The possibility of common infectious mechanisms should be explored.Entities:
Keywords: Great Britain; aetiology; cancer; childhood; epidemiology; space-time clustering
Mesh:
Year: 2013 PMID: 23775892 PMCID: PMC4232877 DOI: 10.1002/ijc.28332
Source DB: PubMed Journal: Int J Cancer ISSN: 0020-7136 Impact factor: 7.396
Numbers of cases for analyses of cross-space-time clustering of childhood cancer in Great Britain, 1969–1993
| Total | Males | Females | ||||
|---|---|---|---|---|---|---|
| Diagnostic group | Birth | Diagnosis | Birth | Diagnosis | Birth | Diagnosis |
| LL(ages 1–4) | 4,140 | 4,343 | 2,361 | 2,483 | 1,779 | 1,860 |
| LL(ages 5–14) | 3,335 | 3,810 | 1,939 | 2,216 | 1,396 | 1,594 |
| HL | 1,226 | 1,364 | 851 | 953 | 375 | 411 |
| NHL | 1,485 | 1,678 | 1,050 | 1,192 | 435 | 486 |
| Astrocytoma | 2,614 | 2,824 | 1,306 | 1,422 | 1,308 | 1,402 |
| IIET | 1,410 | 1,548 | 889 | 976 | 521 | 572 |
| STS | 1,921 | 2,101 | 1,083 | 1,185 | 838 | 916 |
| Osteosarcoma | 669 | 811 | 334 | 408 | 335 | 403 |
| Renal tumors | 1,820 | 1,889 | 920 | 945 | 900 | 944 |
HL: Hodgkin lymphoma; IIET: intracranial and intraspinal embryonal tumors; LL: lymphoid leukemia; NHL: non-Hodgkin lymphoma; STS: soft tissue sarcomas.
Cross-space-time clustering of cases of HL and NHL with other diagnostic groups
| Diagnostic groups | Place of birth and date of birth | Place of birth and date of diagnosis | Place of diagnosis and date of diagnosis |
|---|---|---|---|
| HL × NHL | |||
| HL × Astrocytoma | |||
| HL × IIET | |||
| HL × STS | |||
| HL × Osteosarcoma | |||
| HL × Renal tumors | |||
| NHL × Astrocytoma | |||
| NHL × IIET | |||
| NHL × STS | |||
| NHL × Osteosarcoma | |||
| NHL × Renal tumors |
Statistically significant, defined as p < 0.00067.
HL: Hodgkin lymphoma; IIET: intracranial and intraspinal embryonal tumors; NHL: non-Hodgkin lymphoma; S: strength of clustering ([{observed − expected}/expected] × 100%, counts of pairs that are close in space and time); STS: soft tissue sarcomas.
Cross-space-time clustering of cases of LL with other diagnostic groups
| Diagnostic groups | Place of birth and date of birth | Place of birth and date of diagnosis | Place of diagnosis and date of diagnosis |
|---|---|---|---|
| LL (ages 1–4) × HL | |||
| LL (ages 1–4) × NHL | |||
| LL (ages 1–4) × Astrocytoma | |||
| LL (ages 1–4) × IIET | |||
| LL (ages 1–4) × STS | |||
| LL (ages 1–4) × Osteosarcoma | |||
| LL (ages 1–4) × Renal tumors | |||
| LL (ages 5–14) × HL | |||
| LL (ages 5–14) × NHL | |||
| LL (ages 5–14) × Astrocytoma | |||
| LL (ages 5–14) × IIET | |||
| LL (ages 5–14) × STS | |||
| LL (ages 5–14) × Osteosarcoma | |||
| LL (ages 5–14) × Renal tumors |
Marginally significant, defined as 0.01 > p ≥ 0.00067.
HL: Hodgkin lymphoma; IIET: intracranial and intraspinal embryonal tumors; LL: lymphoid leukemia; NHL: non-Hodgkin lymphoma; S: strength of clustering ([{observed − expected}/expected] × 100%, counts of pairs that are close in space and time).
STS, soft tissue sarcomas
Cross-space-time clustering of cases of LL with other diagnostic groups, by level of population density
| Diagnostic groups | Place of birth and date of birth | Place of birth and date of diagnosis | Place of diagnosis and date of diagnosis |
|---|---|---|---|
| (a) “More densely populated: any” cross-clustering pairs | |||
| LL (ages 1–4) × HL | |||
| LL (ages 1–4) × NHL | |||
| LL (ages 1–4) × Astrocytoma | |||
| LL (ages 1–4) × IIET | |||
| LL (ages 1–4) × STS | |||
| LL (ages 1–4) × Osteosarcoma | |||
| LL (ages 1–4) × Renal tumors | |||
| LL (ages 5–14) × HL | |||
| LL (ages 5–14) × NHL | |||
| LL (ages 5–14) × Astrocytoma | |||
| LL (ages 5–14) × IIET | |||
| LL (ages 5–14) × STS | |||
| LL(ages 5–14) × Osteosarcoma | |||
| LL (ages 5–14) × Renal tumors | |||
| (b) “Less densely populated: any” cross clustering pairs | |||
| LL (ages 1–4) × HL | |||
| LL (ages 1–4) × NHL | |||
| LL (ages 1–4) × Astrocytoma | |||
| LL (ages 1–4) × IIET | |||
| LL (ages 1–4) × STS | |||
| LL (ages 1–4) × Osteosarcoma | |||
| LL (ages 1–4) × Renal tumors | |||
| LL (ages 5–14) × HL | |||
| LL (ages 5–14) × NHL | |||
| LL (ages 5–14) × Astrocytoma | |||
| LL (ages 5–14) × IIET | |||
| LL (ages 5–14) × STS | |||
| LL (ages 5–14) × Osteosarcoma | |||
| LL (ages 5–14) × Renal tumors | |||
Marginally significant, defined as 0.01 > p ≥ 0.00067.
HL: Hodgkin lymphoma; IIET: intracranial and intraspinal embryonal tumors; LL: lymphoid leukemia; NHL: non-Hodgkin lymphoma; S: strength of clustering ([{observed – expected} / expected] × 100%, counts of pairs that are close in space and time); STS: soft tissue sarcomas
Cross-space-time clustering of cases of HL and NHL with other diagnostic groups, by level of population density
| Diagnostic groups | Place of birth and date of birth | Place of birth and date of diagnosis | Place of diagnosis and date of diagnosis |
|---|---|---|---|
| (a) “More densely populated: any” cross-clustering pairs | |||
| HL × NHL | |||
| HL × Astrocytoma | |||
| HL × IIET | |||
| HL × STS | |||
| HL × Osteosarcoma | |||
| HL × Renal tumors | |||
| NHL × Astrocytoma | |||
| NHL × IIET | |||
| NHL × STS | |||
| NHL × Osteosarcoma | |||
| NHL × Renal tumors | |||
| (b) “Less densely populated: any” cross-clustering pairs | |||
| HL × NHL | |||
| HL × Astrocytoma | |||
| HL × IIET | |||
| HL × STS | |||
| HL × Osteosarcoma | |||
| HL × Renal tumors | |||
| NHL × Astrocytoma | |||
| NHL × IIET | |||
| NHL × STS | |||
| NHL × Osteosarcoma | |||
| NHL × Renal tumors | |||
Statistically significant, defined as p < 0.00067.
Marginally significant, defined as 0.01 > p ≥ 0.00067.
HL: Hodgkin lymphoma; IIET: intracranial and intraspinal embryonal tumors; NHL: non-Hodgkin lymphoma; S: strength of clustering ([{observed – expected}/expected] × 100%, counts of pairs that are close in space and time); STS: soft tissue sarcomas.